No abstract

BackgroundPeripheral blood stem cell transplantation (PBSCT) has reduced morbidity and mortality and it is probably one of the most important of the autologous transplantations.PurposeThe objective is to describe the complications (neutropenic fever and mucositis) and progress observed in haematological patients undergoing a PBSCT.Material and methodsObservational, descriptive and retrospective study carried out during 2013 in a 500-bed university hospital. All patients undergoing a PBSCT were included in the study.Two different groups were established, depending on the conditioning regime administered, depending on the usual clinical practice.Group A: Patients treated with BCNU, etoposide and cytosine arabinoside and melphalan (BEAM)Group B: Patients treated with melphalanData collected included: sex, age, types of conditioning regimen, NF and mucositis during the bone marrow aplasia phase, as well as the patients’ situation three months after the PBSCT.ResultsDuring the bone marrow aplasia phase patients presented neutropenic fever and mucositis (Table 1).Three months after the PBSCT, nine patients in group A presented a complete response, two patients partial response, and one patient success. In group B, ten patients presented complete response and one patient partial response.Abstract CP-131 Table 1Number of patientsGroup ANumber of patientsGroup B1. Neutropenic fever10111.1. No microbiological isolation7101.1.1. Non-persistent571.1.2. Persistent231.2. Microbiological isolation311.2.1. Bacteraemia212. Mucositis1192.1. Required parenteral nutrition74ConclusionMost of the patients undergoing a PBSCT presented neutropenic fever and mucositis. Eight of them required an antimicrobial treatment of high complexity and 11 required parenteral nutritional support.Three months after the PBSCT, the number of complete responses in group B was superior to those in group A.References and/or AcknowledgementsI wish to acknowledge the help provided by the pharmacy members.No conflict of interest.

Background A recently-published meta-analysis describes the risk of thromboembolic events (TEs) associated with anti-growth factor receptors such as cetuximab and panitumumab. Purpose To describe the frequency of TEs related to cetuximab and panitumumab use. Likewise, to detail adverse reactions (ARs) and their severity. Materials and Methods Retrospective descriptive study in a 500-bed university hospital performed from January 2010 to September 2012. All patients who had been treated with cetuximab or panitumumab were reviewed. In a database we recorded: sex, age, underlying disease, drug, dose reduction if it was necessary, number of cycles administered, ARs and degree of severity according to Common Toxicity Criteria. The information was extracted from patients’ medical records and from pharmacy service records. ResultsTwenty-four patients were included, 12 were men. Mean sample age was 61 years. The main underlying disease was colorectal cancer with liver and lung metastases (41.2%). Mean duration of treatment was 10.7 cycles/patient. All patients received cetuximab in combination regimens with fluoropyrimidines, platinum and irinotecan. Four patients were treated with panitumumab. ARs appeared in 95.8% of the sample. There were 153 ARs, 88.9% during treatment with cetuximab. (Table 1). Two cases of deep vein thrombosis (DVT) during treatment with cetuximab were reported; none with panitumumab. Grade 1 toxicity represented 44.5% of all ARs, 40.5% were grade 2, 13.7% grade 3 and 1.3% grade 4. Due to ARs, three patients required dosage reduction, all related to cetuximab schedules. Conclusions Two cases of DVT were reported in patients treated with different cetuximab chemotherapy schedules. It is difficult to establish a relationship between ARs and the drugs used. Further studies are needed to clarify the association of TE and cetuximab. The rest of AR founded, are described in the product information. It is necessary a higher foresight to establish preventive measures to avoid or reduce AR toxicity. Abstract DGI-059 Table 1 AR % of patients Rash 79.2 Paresthesia 66.7 Transaminases 54.2 Asthenia 45.8 Diarrhoea 37.5 Neutropenia 29.2 Anaemia 25.0 Tricomegalia 25.0 No conflict of interest.